Lasofoxifene treatment of breast cancer
AssigneeDuke University
InventorsKaitlyn ANDREANO, Ching-yi CHANG, Donald P. McDONNELL, Stephanie L. GAILLARD
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
Claims29
1-256. (canceled)
A method of reducing metastasis of estrogen receptor positive (ER+) cancer in a patient, wherein the cancer has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (ESR1) gene, the method comprising:
- administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.